水野　隆一 (ミズノ　リュウイチ)

Mizuno, Ryuichi

写真a

所属（所属キャンパス）

医学部 泌尿器科学教室 （信濃町）

職名

准教授
このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 1992年04月
    -
    1998年03月

    慶應義塾大学, 医学部

    大学, 卒業

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

    Shigeta K., Kosaka T., Hongo H., Yanai Y., Matsumoto K., Morita S., Mizuno R., Shinojima T., Kikuchi E., Oya M.

    International Journal of Clinical Oncology （International Journal of Clinical Oncology)  24 （ 5 ） 546 - 553 2019年05月

    ISSN  13419625

    　概要を見る

    © 2019, Japan Society of Clinical Oncology. Background: Our specific aim was to investigate the prognostic value of effective duration of first androgen deprivation therapy (ADT) and to evaluate the clinical impact on early docetaxel administration with oncological outcomes in castration-resistant prostate cancer (CRPC) patients treated with docetaxel. Methods: We identified 148 mCRPC patients who were treated with 75 mg/m 2 docetaxel. We defined 16 months as the threshold for the effective duration of ADT, and defined 12 months as the cut-off time for starting docetaxel from the onset of CRPC. Univariate and multivariate analyses were conducted to investigate the prognostic indicators that influenced the survival outcomes. Results: Overall, 81 (54.7%) patients died. The median 1st ADT response was 22.2 months and the median time interval from CRPC onset to docetaxel treatment was 11.7 months. Multivariate analysis indicated that visceral metastasis, bone metastasis extent of disease (EOD) ≥ 2, and effective duration of ADT < 16 months were the independent prognostic indicators for progression-free survival (PFS). Referring to cancer-specific survival (CSS), besides visceral metastasis and effective duration of ADT < 16 months, late docetaxel treatment ≥ 12 months became as the predictors for poor prognosis. Among the ADT poor-responder group (ADT < 16 months), Kaplan–Meier method showed that 1-year and 2-year CSS rates were 96.0% and 80.0% in the patients who introduced docetaxel in early setting (< 12 months), which were significantly higher than those who introduced in late settings (93.6% and 30.8%, respectively, p < 0.001). Conclusion: CRPC patients who had poor response during 1st ADT would obtain survival benefit by introducing docetaxel treatment in early stage.

  • Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma

    Mizuno R., Oya M.

    Gan to kagaku ryoho. Cancer &amp; chemotherapy （Gan to kagaku ryoho. Cancer &amp; chemotherapy)  46 （ 1 ） 50 - 53 2019年01月

    ISSN  03850684

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer

    Matsumoto K., Akita H., Narita K., Hashiguchi A., Takamatsu K., Takeda T., Kosaka T., Mizuno R., Kikuchi E., Oya M., Jinzaki M.

    Prostate Cancer and Prostatic Diseases （Prostate Cancer and Prostatic Diseases)  2019年

    ISSN  13657852

    　概要を見る

    © 2019, Springer Nature America, Inc. Background: Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of EPE is controversial. Methods: We retrospectively analyzed the records of 233 consecutive patients who underwent preoperative MRI and radical prostatectomy. We designated their tumors as anterior or posterior, and evaluated the correlation between the TCL measured by MRI and microscopic EPE in the radical prostatectomy specimen. Then, we created the predicted probability curves for EPE versus TCL for anterior and posterior prostate cancer. Results: There were 109 patients (47%) with an anterior tumor and 124 patients (53%) with a posterior tumor. Postoperative pathological analysis confirmed pT3 in 18 patients (17%) with an anterior tumor and in 53 patients (43%) with a posterior tumor. Multivariate analysis demonstrated that the zonal origin of the tumor was an independent predictive factor for EPE. We developed separate probability curves of EPE versus TCL for anterior and posterior prostate cancer, which revealed that anterior tumors were less likely to invade the extraprostatic tissues. Among patients whose TCL was 10–20 mm, 9/32 patients (28%) with an anterior tumor had EPE compared with 24/45 patients (53%) with a posterior tumor (p = 0.036). The decision curve of this EPE predictive model had high clinical efficacy. Conclusions: Our results indicate that anterior tumors have more favorable pathological characteristics than posterior tumors with the same TCL measured by MRI. We constructed two separate predicted probability curves for EPE after discriminating anterior and posterior tumors, which will be useful for decision making in clinical practice.

  • Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

    Ito K., Masunaga A., Tanaka N., Mizuno R., Shirotake S., Yasumizu Y., Ito Y., Miyazaki Y., Hagiwara M., Kanao K., Mikami S., Momma T., Masuda T., Nakagawa K., Oyama M., Asano T., Oya M.

    Japanese Journal of Clinical Oncology （Japanese Journal of Clinical Oncology)  49 （ 1 ） 69 - 76 2019年

    ISSN  03682811

    　概要を見る

    © The Author(s) 2018. Published by Oxford University Press. All rights reserved. Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation—including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase—were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47%. Female gender, Karnofsky performance status <80%, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate dehydrogenase decline were not independent predictors. When all patients were stratified by these independent factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in progression-free survival rates between the groups (P < 0.0001). Furthermore, there were also significant differences in overall survival rates between the groups (P < 0.0001). Conclusions: Integration of post-treatment neutrophil-to-lymphocyte ratio value with pretreatment factors may lead to the establishment of effective predictive model for disease progression in patients with metastatic clear cell renal cell carcinoma who received first-line targeted therapies.

  • The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy

    Takamatsu K., Matsumoto K., Shojo K., Tanaka N., Takeda T., Morita S., Kosaka T., Mizuno R., Shinojima T., Kikuchi E., Asanuma H., Oya M.

    Urologic Oncology: Seminars and Original Investigations （Urologic Oncology: Seminars and Original Investigations)  2019年

    ISSN  10781439

    　概要を見る

    © 2019 Elsevier Inc. Objective: To investigate the influence of the zonal origin of prostate cancer and extraprostatic extension on biochemical recurrence (BCR). Patients and methods: We included 638 consecutive patients undergoing radical prostatectomy between 2005 and 2015 who did not receive neoadjuvant/adjuvant therapy. The largest lesion was defined as the index tumor. We categorized each patient into the transition zone (TZ) or peripheral zone (PZ) group based on the lesion where the index tumor existed. Differences in the BCR defined as increasing prostate-specific antigen rate between groups were examined by Kaplan-Meier analysis and the Cox proportional hazards model. Results: There were 293 (46%) patients with TZ cancer and 345 (54%) with PZ cancer. TZ cancer was significantly associated with a higher prostate-specific antigen (P = 0.012), lower biopsy positive core rate (P = 0.020), lower pathological Gleason score (P = 0.017), lower pathological stage (P = 0.002), and lower rate of seminal vesicle invasion (P = 0.002). During a median follow-up period of 59 months, 79 patients (12%) developed BCR. In the entire cohort, the PZ origin (hazard ratio: 1.68, P = 0.033) and extraprostatic extension were independent risk factors for BCR. The 3-, 5-, and 7-year BCR-free survival rates of patients with pT3a TZ cancer were 89%, 88%, and 86%, respectively, which were significantly better than those of patients with pT3a PZ cancer (80%, 74%, and 62%, P = 0.012), but were similar to those of the pT2 cancer cohort (92%, 91%, and 90%, P = 0.376). Conclusion: TZ cancer had more favorable pathological characteristics and oncological outcome than PZ cancer especially in pT3a cases.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 放射線照射後の膀胱穿孔に伴う急性腎不全の一例

    伊藤祐二郎、松本一宏、金子　剛、井手広樹、水野隆一、大東貴志、村井　勝

    日本泌尿器科学会東京地方会 (第582回) , 

    2006年06月
    , 

    口頭発表（一般）

  • 腎細胞癌におけるEts-1の発現

    大家 基嗣

    第15回泌尿器科分子・細胞研究会 (京都) , 

    2006年02月
    , 

    口頭発表（一般）

  • 膀胱癌診断における超拡大内視鏡Endocytoscopeの使用経験

    大東貴志、小堺紀英、水野隆一、宮島哲、中川健、中島淳、村井勝

    第19回日本Endourology・ESWL学会総会 (東京) , 

    2005年11月
    , 

    口頭発表（一般）

  • 両側腎盂尿管術後精巣転移の１例

    井手広樹、菊地栄次、水野隆一、村井勝

    第576回日本泌尿器科学会東京地方会 (東京) , 

    2005年07月
    , 

    ポスター発表

  • 感度を90%にした場合の生検で見逃されると予想される前立腺癌の病理学的検討

    内田康光，大東貴志，水野隆一，菊地栄次，宮嶋　哲，堀口　裕，中川　健，大家基嗣，中島　淳，丸茂　健，村井　勝

    第93回日本泌尿器科学会総会 (東京) , 

    2005年04月
    , 

    ポスター発表

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • T細胞レパトアを組入れた進行性腎細胞癌に対する免疫チェックポイント阻害薬選択基準

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 水野 隆一, 基盤研究(C), 補助金,  研究代表者

  • リキッドバイオプシーによる進行性腎細胞癌新規分子標的治療アルゴリズムの確立

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 水野　隆一, 基盤研究(C), 補助金,  研究代表者

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 泌尿器科学講義

    2023年度

  • 泌尿器科学講義

    2022年度

  • 泌尿器科学講義

    2021年度

  • 泌尿器科学講義

    2020年度

  • 泌尿器科学講義

    2019年度

このページの先頭へ▲

担当経験のある授業科目 【 表示 ／ 非表示 】

  • 泌尿器科学

    慶應義塾

    2015年04月
    -
    2016年03月
    , 

    通年

このページの先頭へ▲